➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Colorcon
Johnson and Johnson
Dow
Express Scripts
Medtronic
Moodys

Last Updated: July 7, 2020

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR PARATHYROID HORMONE

» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for parathyroid hormone

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00000400 Alendronate and/or Parathyroid Hormone for Osteoporosis Completed National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) Phase 2 1999-08-01 This study looks at the effects of two medications, alendronate and parathyroid hormone, on bone mass and on bone formation and bone breakdown in women with osteoporosis. We will randomly select postmenopausal women who have osteoporosis to receive laboratory-produced human parathyroid hormone (hPTH), or alendronate, or both for 2.5 years. Study participants will return to the study center periodically to have their bone mass measured and to give blood and urine samples for tests of bone formation and breakdown and for other laboratory tests. Those who complete the study are eligible for one or two 12 month extension studies.
NCT00000400 Alendronate and/or Parathyroid Hormone for Osteoporosis Completed Massachusetts General Hospital Phase 2 1999-08-01 This study looks at the effects of two medications, alendronate and parathyroid hormone, on bone mass and on bone formation and bone breakdown in women with osteoporosis. We will randomly select postmenopausal women who have osteoporosis to receive laboratory-produced human parathyroid hormone (hPTH), or alendronate, or both for 2.5 years. Study participants will return to the study center periodically to have their bone mass measured and to give blood and urine samples for tests of bone formation and breakdown and for other laboratory tests. Those who complete the study are eligible for one or two 12 month extension studies.
NCT00000427 Effects of Parathyroid Hormone in Men With Osteoporosis Completed National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) Phase 3 1999-09-01 Alendronate is a drug that blocks or reduces bone loss, while parathyroid hormone (PTH) stimulates the formation of new bone. The purpose of this study is to compare the bone-building effects of PTH alone, alendronate alone, and both PTH and alendronate in men with osteoporosis over a two-and-a-half year period.
NCT00000427 Effects of Parathyroid Hormone in Men With Osteoporosis Completed Massachusetts General Hospital Phase 3 1999-09-01 Alendronate is a drug that blocks or reduces bone loss, while parathyroid hormone (PTH) stimulates the formation of new bone. The purpose of this study is to compare the bone-building effects of PTH alone, alendronate alone, and both PTH and alendronate in men with osteoporosis over a two-and-a-half year period.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for parathyroid hormone

Condition Name

Condition Name for parathyroid hormone
Intervention Trials
Osteoporosis 39
Vitamin D Deficiency 33
Secondary Hyperparathyroidism 27
Chronic Kidney Disease 23
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for parathyroid hormone
Intervention Trials
Hyperparathyroidism 59
Kidney Diseases 49
Renal Insufficiency, Chronic 48
Osteoporosis 44
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for parathyroid hormone

Trials by Country

Trials by Country for parathyroid hormone
Location Trials
United States 507
Canada 43
Spain 31
Mexico 22
Brazil 19
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for parathyroid hormone
Location Trials
New York 41
California 29
Texas 27
Florida 27
Pennsylvania 25
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for parathyroid hormone

Clinical Trial Phase

Clinical Trial Phase for parathyroid hormone
Clinical Trial Phase Trials
Phase 4 59
Phase 3 56
Phase 2/Phase 3 5
[disabled in preview] 49
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for parathyroid hormone
Clinical Trial Phase Trials
Completed 135
Recruiting 37
Unknown status 21
[disabled in preview] 21
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for parathyroid hormone

Sponsor Name

Sponsor Name for parathyroid hormone
Sponsor Trials
Amgen 16
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 15
Shire 13
[disabled in preview] 10
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for parathyroid hormone
Sponsor Trials
Other 239
Industry 92
NIH 51
[disabled in preview] 10
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
AstraZeneca
Dow
Express Scripts
Moodys
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.